Platinum-resistant Ovarian Cancer Recruiting Phase 1 / 2 Trials for Ifebemtinib (DB17570)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05551507IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian CancerTreatment